Unnamed: 0,title,date,stock,sentiment
147678.0,"The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study",2020-06-09 06:05:00-04:00,BCLI,positive
147679.0,BrainStorm Announces That Pivotal Phase 3 Trial Remains On Track For Topline Data In Q4-2020,2020-06-02 06:04:00-04:00,BCLI,neutral
147680.0,84 Biggest Movers From Yesterday,2020-05-08 05:34:00-04:00,BCLI,neutral
147681.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,BCLI,negative
147682.0,Brainstorm Cell Q1 EPS $(0.320) Misses $(0.220) Estimate,2020-05-07 06:42:00-04:00,BCLI,negative
147683.0,BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union,2020-05-07 05:33:00-04:00,BCLI,neutral
147684.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,BCLI,neutral
147685.0,Sankesh Abbhi Reports 9.04% Stake In Brainstorm Cell Therapeutics Inc As Of March 30,2020-04-08 06:10:00-04:00,BCLI,neutral
147686.0,BrainStorm Wins $1.5M Non-Dilutive Grant By Israel Innovation Authority,2020-04-03 07:00:00-04:00,BCLI,positive
147687.0,BrainStorm Appoints Prof. Jacob Frenkel Chairman of the Board of Directors,2020-03-31 10:52:00-04:00,BCLI,neutral
147688.0,Brainstorm Therapeutics Shares Pare All Recent Gains Since Trader Circulation Of Co. Tweet; Shares Still Up 8% for Session,2020-03-24 11:33:00-04:00,BCLI,positive
147689.0,"Brainstorm Shares Spike To Session High, Up 23%, As Traders Circulate Earlier Tweet From Co. 'BrainStorm hereby appeals to the public to volunteer, donate bone marrow for the production of breakthrough therapy designed to treat the coronavirus...'",2020-03-24 11:26:00-04:00,BCLI,positive
147690.0,130 Biggest Movers From Yesterday,2020-03-18 06:06:00-04:00,BCLI,neutral
147691.0,94 Stocks Moving In Tuesday's Mid-Day Session,2020-03-17 12:41:00-04:00,BCLI,neutral
147692.0,BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19,2020-03-16 05:07:00-04:00,BCLI,neutral
147693.0,100 Biggest Movers From Friday,2020-03-09 05:25:00-04:00,BCLI,neutral
147694.0,60 Stocks Moving In Friday's Mid-Day Session,2020-03-06 12:11:00-05:00,BCLI,neutral
147695.0,BrainStorm Cell Therapeutics Prices 1.25M Common Stock Offering At $8/Share,2020-03-06 09:26:00-05:00,BCLI,neutral
147696.0,101 Biggest Movers From Yesterday,2020-03-06 04:28:00-05:00,BCLI,neutral
147697.0,95 Biggest Movers From Yesterday,2020-02-27 05:18:00-05:00,BCLI,neutral
147698.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,BCLI,negative
147699.0,80 Biggest Movers From Yesterday,2020-02-26 05:32:00-05:00,BCLI,neutral
147700.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-02-25 12:24:00-05:00,BCLI,neutral
147701.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-25 10:15:00-05:00,BCLI,neutral
147702.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,BCLI,negative
147703.0,77 Biggest Movers From Yesterday,2020-02-25 04:30:00-05:00,BCLI,neutral
147704.0,55 Stocks Moving In Monday's Mid-Day Session,2020-02-24 13:10:00-05:00,BCLI,neutral
147705.0,94 Biggest Movers From Friday,2020-02-24 04:53:00-05:00,BCLI,neutral
147707.0,80 Biggest Movers From Yesterday,2020-02-19 04:28:00-05:00,BCLI,neutral
147708.0,35 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-02-18 08:25:00-05:00,BCLI,neutral
147709.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,BCLI,negative
147710.0,77 Biggest Movers From Yesterday,2020-02-14 04:59:00-05:00,BCLI,neutral
147711.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-13 10:26:00-05:00,BCLI,neutral
147712.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,BCLI,negative
147713.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,BCLI,neutral
147714.0,94 Biggest Movers From Yesterday,2020-02-12 05:13:00-05:00,BCLI,neutral
147715.0,71 Stocks Moving In Tuesday's Mid-Day Session,2020-02-11 12:21:00-05:00,BCLI,neutral
147716.0,BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn Regulatory Pathway for Approval in ALS,2020-02-11 06:04:00-05:00,BCLI,positive
147717.0,BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference,2020-02-04 04:53:00-05:00,BCLI,neutral
147718.0,BrainStorm Receives Notice of Intention to Grant Additional EU Patent for NurOwn,2020-01-29 05:06:00-05:00,BCLI,positive
147719.0,BrainStorm Issues 2019 Letter to Shareholders,2019-12-18 05:18:00-05:00,BCLI,neutral
147720.0,BrainStorm Cell Therapeutics Reports Mount Sinai Medical Center Has Contracted With Co. As Clinical Study Stie For Co.'s Phase 2 Label For NurOwn,2019-11-25 06:03:00-05:00,BCLI,neutral
147721.0,"Brainstorm Cell Therapeutics 13D From Joseph Daly Shows 4.58% Stake, Karina Daly Shows 0.37% Stake, EssigPR Shows 0.61% Stake",2019-11-21 07:29:00-05:00,BCLI,neutral
147722.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,BCLI,positive
147723.0,"BrainStorm Cell Therapeutics Reports Receives $495.33K Grant From National Multiple Sclerosis Society To Advance Co.'s Phase 2 Open-Label, Multicenter Clinical Trial Of Repeated Intrathecal Administration Of NurOwn",2019-11-14 07:09:00-05:00,BCLI,positive
147724.0,BrainStorm Cell Therapeutics Announces COO Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting,2019-11-12 04:07:00-05:00,BCLI,neutral
147725.0,BrainStorm Cell Therapeutics' Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue,2019-10-28 07:49:00-04:00,BCLI,positive
147726.0,BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference on October 29,2019-10-25 03:50:00-04:00,BCLI,positive
147727.0,BrainStorm Says NurOwn Phase 3 ALS Clinical Trial Now Fully Enrolled,2019-10-11 03:50:00-04:00,BCLI,neutral
147728.0,BrainStorm Cell Therapeutics Granted a Patent for NurOwn Cellular Therapeutic Technology,2019-10-07 08:17:00-04:00,BCLI,positive
147729.0,BrainStorm Cell Therapeutics To Present NurOwn Phase 2 Biomarker Data At North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting,2019-10-02 06:48:00-04:00,BCLI,neutral
147730.0,"BrainStorm Names Preetam Shah, Ph.D., M.B.A., as CFO",2019-09-09 03:42:00-04:00,BCLI,neutral
147731.0,BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress on Friday September 13,2019-09-06 04:40:00-04:00,BCLI,neutral
147732.0,Brainstorm Cell Q2 EPS $(0.23) Beats $(0.24) Estimate,2019-08-13 07:30:00-04:00,BCLI,neutral
147733.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,BCLI,neutral
147734.0,"Earnings Scheduled For August 13, 2019",2019-08-13 04:11:00-04:00,BCLI,neutral
147735.0,"The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO",2019-08-11 15:46:00-04:00,BCLI,positive
147736.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,BCLI,neutral
147737.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,BCLI,neutral
147738.0,"Brainstorm Therapeutics Shares Up 6% Over Last Few Mins; Co. Tweeted 'ABC Nightline' Will Air A Segment On ALS, Including The Company's NurOwn Phase 3 Trial",2019-08-08 15:59:00-04:00,BCLI,positive
147739.0,Third Clinical Site Initiated For BrainStorm Cell Therapeutic's Phase 2 Progressive MS Study,2019-07-02 08:16:00-04:00,BCLI,neutral
147740.0,BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers 33rd Annual Meeting,2019-05-31 04:27:00-04:00,BCLI,neutral
147741.0,BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study,2019-05-30 03:13:00-04:00,BCLI,neutral
147742.0,Brainstorm Cell Q1 EPS $(0.24) Misses $(0.07) Estimate,2019-05-10 17:00:00-04:00,BCLI,negative
147743.0,BrainStorm's Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases,2019-04-30 04:07:00-04:00,BCLI,neutral
147744.0,BrainStorm Scientific Earlier Announced Two Abstracts Accepted For Presentation At 71st American Academy Of Neurology Annual Meeting,2019-03-28 08:58:00-04:00,BCLI,positive
147745.0,Brainstorm Cell Therapeutics shares are trading higher after the company announced it was granted an additional European patent for its NurOwn.,2019-03-26 08:53:00-04:00,BCLI,positive
147746.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-03-26 08:39:00-04:00,BCLI,neutral
147747.0,BrainStorm Announces Grant of Additional New European Patent for NurOwn,2019-03-26 06:34:00-04:00,BCLI,positive
147748.0,BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS,2019-03-14 04:01:00-04:00,BCLI,neutral
147749.0,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",2019-03-12 07:47:00-04:00,BCLI,positive
147750.0,Brainstorm Cell Application To Allow ALS Patient Access To Nurown Under Hospital Exemption Pathway Was Recently Approved By Israeli Health Ministry,2019-03-12 06:18:00-04:00,BCLI,positive
147751.0,Brainstorm Announces First Contracted US Clinical Site For Phase 2 Progressive MS Study,2019-02-22 07:45:00-05:00,BCLI,neutral
147752.0,BrainStorm Granted Additional Patent for NurOwn in Israel,2019-01-22 08:45:00-05:00,BCLI,positive
147753.0,"BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA",2019-01-11 04:25:00-05:00,BCLI,neutral
147754.0,BrainStorm CEO Chaim Lebovits Sends 2018 Letter To Shareholders,2018-12-27 07:38:00-05:00,BCLI,neutral
147755.0,BrainStorm Expands Manufacturing of NurOwn for Phase 2 Progressive MS Trial,2018-12-26 03:50:00-05:00,BCLI,positive
147756.0,60 Biggest Movers From Friday,2018-12-24 04:35:00-05:00,BCLI,neutral
147757.0,Brainstorm Cell Therapeutics shares are trading higher after announcing the FDA accepted the company's investigational new drug application for progressive multiple sclerosis.,2018-12-17 07:56:00-05:00,BCLI,positive
147758.0,FDA Accepts BrainStorm's NurOwn IND Application For Progressive Multiple Sclerosis,2018-12-17 07:34:00-05:00,BCLI,positive
147759.0,BrainStorm Cell Therapeutics Announces Submission Of IND For NurOwn In Progressive Multiple Sclerosis,2018-11-19 08:06:00-05:00,BCLI,neutral
147760.0,Brainstorm Cell Q3 EPS $(0.15) Misses $(0.10) Estimate,2018-10-29 08:06:00-04:00,BCLI,negative
147761.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,BCLI,neutral
147762.0,BrainStorm Granted New U.S. Patent For Industrial Scale Manufacturing Of Its NurOwn Manufacturing Process,2018-09-13 07:33:00-04:00,BCLI,positive
147763.0,BrainStorm Appoints Arturo Araya as Chief Commercial Officer,2018-09-04 08:17:00-04:00,BCLI,neutral
147764.0,"BrainStorm Cell Therapeutics Reports Interim Safety Analysis in Phase 3 Trial of NurOwn Therapy for ALS, Data Safety Monitoring Board Said There's No Significant Safety Concerns And Recommended The Trial To Continue As Planned",2018-08-23 08:23:00-04:00,BCLI,positive
147765.0,BrainStorm Cell Therapeutics Reports Granting Of New European Patent For NurOwn Until 2029,2018-07-25 09:04:00-04:00,BCLI,positive
147766.0,Brainstorm Cell Q2 EPS $(0.16) Down From $(0.06) YoY,2018-07-23 08:01:00-04:00,BCLI,neutral
147767.0,BrainStorm Granted Japanese Patent for NurOwn,2018-07-05 07:32:00-04:00,BCLI,positive
147768.0,20 Stocks Moving In Tuesday's Pre-Market Session,2018-07-03 08:04:00-04:00,BCLI,neutral
147769.0,5 Stocks Moving In Wednesday's After-Hours Session,2018-06-27 18:12:00-04:00,BCLI,neutral
147770.0,Brainstorm Cell Therapeutics Says It Won't Provide ALS Stem Cell Treatment Under 'Right to Try' Act At This Time Due To Failure To Find A Way For All Patients To Afford Treatment,2018-06-26 07:39:00-04:00,BCLI,negative
147771.0,"'Oh, great, but probably wiser for $BCLI to focus on completing the phase 3 study.'-STAT's Adam Feuerstein Tweets",2018-06-25 09:49:00-04:00,BCLI,positive
147772.0,"'$BCLI NurOwn for ALS. In the phase 2, there was no difference from placebo on ALSFRS scale. In fact, by 12 weeks follow-up, placebo patients were progressing slower. But sure, make a profit on RTT patients.' - -tweet from STAT News' Adam F",2018-06-20 15:01:00-04:00,BCLI,positive
147773.0,Brainstorm Cell Therapeutics Option Alert: Jul 20 $2.5 Calls Sweep (24) at the Bid: 500 @ $2.461 vs 2 OI; Ref=$5.13,2018-06-04 10:33:00-04:00,BCLI,positive
147774.0,BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention,2018-05-30 03:48:00-04:00,BCLI,neutral
147775.0,37 Stocks Moving In Tuesday's Mid-Day Session,2018-05-29 12:44:00-04:00,BCLI,neutral
147776.0,"BrainStorm Cell Therapeutics Issues Statement on 'Right to Try' Legislation, Says It Is Currently Assessing The Legislation And Its Implications and Will Issue a Formal Policy On It In Early June",2018-05-25 09:41:00-04:00,BCLI,neutral
147777.0,22 Stocks Moving In Thursday's Pre-Market Session,2018-05-17 08:01:00-04:00,BCLI,neutral
147778.0,"H.C. Wainwright Initiates Coverage On Brainstorm Cell with Buy Rating, Announces $11 Price Target",2018-05-15 09:36:00-04:00,BCLI,neutral
147779.0,Brainstorm Cell Q1 EPS $(0.12) Beats $(0.32) Estimate,2018-05-14 08:04:00-04:00,BCLI,neutral
147780.0,"Earnings Scheduled For May 14, 2018",2018-05-14 05:06:00-04:00,BCLI,neutral
147781.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-13 10:06:00-04:00,BCLI,neutral
147782.0,BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London,2018-05-09 03:43:00-04:00,BCLI,positive
147783.0,"Brainstorm Cell Therapeutics Shares Spike On Volume, Boston Globe Publishes: 'Trials for potential ALS treatment spark cautious hope' Wherein CEO Lebovits Says of NurOwn Treatment: 'We have seen wonderful results in a smaller patient population'",2018-04-05 14:41:00-04:00,BCLI,positive
147784.0,BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients,2018-03-28 05:58:00-04:00,BCLI,neutral
147785.0,BrainStorm Reports FY17 EPS $(0.26) vs $(0.27) In Prior Year Period,2018-03-08 06:32:00-05:00,BCLI,neutral
147786.0,BrainStorm's NurOwn Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles,2018-02-07 06:13:00-05:00,BCLI,positive
147787.0,BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn,2018-01-03 07:44:00-05:00,BCLI,positive
147788.0,26 Biggest Movers From Friday,2018-01-02 04:43:00-05:00,BCLI,neutral
147789.0,BrainStorm Cell Therapeutics Earlier Issues '17 Letter To Shareholders,2017-12-29 08:09:00-05:00,BCLI,neutral
147790.0,BrainStorm's Abstracts on Phase 2 NurOwn Biomarkers Accepted for Presentation at the International Symposium on ALS/MND,2017-11-29 06:33:00-05:00,BCLI,positive
147791.0,BrainStorm Cell Therapeutics Names Eyal Rubin CFO,2017-11-02 09:03:00-04:00,BCLI,neutral
147792.0,BrainStorm Reports Q3 EPS $(0.13) vs $(0.16) Est.,2017-10-17 07:03:00-04:00,BCLI,neutral
147793.0,BrainStorm  Cell Therapeutics Announces Enrollment of First Patients in Phase 3 Trial of NurOwn® in ALS,2017-10-16 04:11:00-04:00,BCLI,neutral
147794.0,Brainstorm Cell Therapeutics Reports Q2 EPS $(0.06) vs $(0.05) In Same Qtr. Last Year,2017-08-14 18:03:00-04:00,BCLI,neutral
147795.0,15 Biggest Mid-Day Gainers For Friday,2017-07-21 12:22:00-04:00,BCLI,neutral
147796.0,Mid-Morning Market Update: Markets Open Lower; General Electric Profit Beats Expectations,2017-07-21 10:11:00-04:00,BCLI,positive
147797.0,22 Stocks Moving In Friday's Pre-Market Session,2017-07-21 08:12:00-04:00,BCLI,neutral
147799.0,Brainstorm Awarded $16M Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn in ALS,2017-07-21 06:13:00-04:00,BCLI,positive
147800.0,"BrainStorm Announces Agreements with Mass. General Hospital, California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn in ALS",2017-07-18 03:39:00-04:00,BCLI,positive
147801.0,BrainStorm Transferring Technology to City of Hope for U.S. Production of NurOwn for Phase 3 ALS Study,2017-05-16 04:43:00-04:00,BCLI,positive
147802.0,"BainStorm Q1 EPS $(0.10) vs $(0.30) Est, No Sales",2017-05-15 07:21:00-04:00,BCLI,negative
147803.0,BrainStorm Reports Publication of NurOwn Autism Research Study,2017-04-19 09:07:00-04:00,BCLI,neutral
147804.0,BrainStorm Cell Therapeutics Reports 4Q Loss/Share $(0.03) vs $(0.07) Est,2017-03-30 04:28:00-04:00,BCLI,negative
147805.0,"BrainStorm Cell Therapeutics Names Ralph Z. Kern as COO, CMO",2017-03-06 04:22:00-05:00,BCLI,neutral
147806.0,BrainStorm Reports Memorandum of Understanding with Tel Aviv Sourasky Medical Center for NurOwn,2017-03-01 06:47:00-05:00,BCLI,neutral
147807.0,BrainStorm Cell Therapeutics to Distribute CCRM's NurOwn If Approved by Canada's Regulatory Body,2017-02-21 07:11:00-05:00,BCLI,positive
147808.0,BrainStorm Cell Therapeutics Announces City of Hope to Manufacture NurOwn for Phase 3 ALS Clinical Trial,2017-02-16 03:59:00-05:00,BCLI,positive
147809.0,18 Stocks Moving In Tuesday's Pre-Market Session,2016-12-20 08:32:00-05:00,BCLI,neutral
147810.0,15 Biggest Mid-Day Gainers For Monday,2016-12-19 12:43:00-05:00,BCLI,neutral
147811.0,18 Stocks Moving In Monday's Pre-Market Session,2016-12-19 08:27:00-05:00,BCLI,neutral
147812.0,Brainstorm Completes Successful End of Phase 2 Meeting with FDA; Accepts Key Elemets of Phase 3 Trial to Support BLA for NurOwn in ALS,2016-12-19 04:09:00-05:00,BCLI,positive
147813.0,15 Biggest Mid-Day Gainers For Wednesday,2016-12-14 12:29:00-05:00,BCLI,neutral
147814.0,Brainstorm Cell Theraputics Opens 11+% Up After Earlier Presenting In Depth Analyses on NurOwn at International Symposium on ALS/MND,2016-12-14 09:40:00-05:00,BCLI,neutral
147815.0,BrainStorm Cell Therapeutics Reports Q3 EPS $(0.09) vs. Est. $(0.11),2016-11-15 09:08:00-05:00,BCLI,neutral
147816.0,BrainStorm Cell Therapeutics Reports Q2 EPS $(0.05) vs $(0.12) in Same Qtr. Last Year,2016-08-11 08:09:00-04:00,BCLI,neutral
147817.0,12 Biggest Mid-Day Losers For Monday,2016-07-18 13:16:00-04:00,BCLI,negative
147818.0,12 Stocks Moving In Monday's Pre-Market Session,2016-07-18 08:33:00-04:00,BCLI,neutral
147819.0,"BrainStorm Reports Positive Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis, Demonstrated As Safe And Well Tolerated With Higher Response Compared To Placebo",2016-07-18 08:04:00-04:00,BCLI,positive
147820.0,BrainStorm Cell Therapeutics Reports $1.5M Win for Non-Dilutive Grant for '16 from Israel's Office of Chief Scientist,2016-05-12 08:07:00-04:00,BCLI,positive
147821.0,Brainstorm Reports Q4 EPS $(0.07) vs. Est. $(0.15),2016-03-10 07:43:00-05:00,BCLI,neutral
147822.0,Brainstorm Cell Therapeutics ALS Trial Shows Stem Cell Treatment Inhibits Disease Progression in 87% of Patients,2016-01-11 18:44:00-05:00,BCLI,negative
147823.0,Mid-Morning Market Update: Markets Open Higher; Shire To Acquire Baxalta For $32B,2016-01-11 10:07:00-05:00,BCLI,neutral
147824.0,BrainStorm Cell Therapeutics To Begin Phase 2 Multi-Dose NurOWn Trial At Hadassah Medical Center With 24 Patients,2016-01-11 07:35:00-05:00,BCLI,neutral
147825.0,BrainStorm Cell Therapeutics Names Dr. Revital Geffen-Aricha as VP of R&D,2015-12-07 04:07:00-05:00,BCLI,neutral
147826.0,BrainStorm and Octane Biotech Announce Success in Cocoon Application Development Based on Customized Bioreactor for NurOwn® Stem Cells,2015-12-01 08:10:00-05:00,BCLI,positive
147827.0,BrainStorm Awarded Additional $735K Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist,2015-11-30 04:10:00-05:00,BCLI,positive
147828.0,Brainstorm Cell Therapeutics Reports Q3 EPS $(0.14) Vs Est $(0.15),2015-11-17 07:01:00-05:00,BCLI,neutral
147829.0,"Brainstorm Cell Therapeutics Reports Positive DSMB Review in Phase 2 Trial of NurOwn in ALS: Adverse Events, Lab Abnormalities Not Identified, Sees Top-Line Data Available Before End of Q2",2015-11-09 08:20:00-05:00,BCLI,positive
147830.0,BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial,2015-10-07 09:37:00-04:00,BCLI,neutral
147831.0,BrainStorm Cell Therapeutics Names Chaim Lebovits CEO,2015-09-22 17:00:00-04:00,BCLI,neutral
147832.0,8K Filing: Brainstorm Cell Therapeutics To Reduce Authorized Shares Of Stock From 800M to 100M,2015-09-04 16:05:00-04:00,BCLI,positive
147833.0,"Brainstorm Cell Therapeutics CFO Bibring Buys 8,500 Shares @$3.04/Share -Form 4",2015-08-21 09:02:00-04:00,BCLI,positive
147834.0,BrainStorm Cell Therapeutics Reports Q2 Loss $0.12 Vs Est Loss $0.14,2015-08-13 07:05:00-04:00,BCLI,negative
147835.0,BrainStorm Cell Therapeutics Reports Q2 EPS $(0.24) vs. Prior Year Quarter $(0.34),2015-08-13 07:00:00-04:00,BCLI,neutral
147836.0,UPDATE: BrainStorm Cell Therapeutics Reports Closing of Enrollment in Phase 2 Trial of NurOwn in ALS,2015-08-11 08:09:00-04:00,BCLI,neutral
147837.0,BrainStorm Cell Therapeutics Reports Closing of Enrollment in Phase 2 Trial of NurOwn in ALS,2015-08-11 08:07:00-04:00,BCLI,neutral
147838.0,BrainStorm Appoints Yoram Bibring As CFO,2015-08-03 06:56:00-04:00,BCLI,neutral
147839.0,BrainStorm Reports Q1 EPS $(0.12) vs. Est. $(0.13),2015-05-14 07:06:00-04:00,BCLI,neutral
147840.0,UPDATE: BrainStorm Cell Therapeutics Shares Rise 15% Following Release of ALS Data,2015-04-21 07:25:00-04:00,BCLI,positive
147841.0,BrainStorm's NurOwn Demonstrates Statistically Significant Effect in ALS Patients,2015-04-21 06:57:00-04:00,BCLI,positive
147842.0,Morning Market Gainers,2015-04-14 09:42:00-04:00,BCLI,neutral
147843.0,BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data,2015-04-14 07:02:00-04:00,BCLI,positive
147844.0,Brainstorm Cell Therapeutics To Present Positive Data,2015-04-14 07:00:00-04:00,BCLI,positive
147845.0,Here's The Tweet That Caused Shares Of Brainstorm Cell Therapeutics To Spike,2015-04-10 12:55:00-04:00,BCLI,positive
147846.0,Brainstorm Cell Therapeutics Shares Move Higher; May be Attributed to Dr. Sanjay Gupta Tweet,2015-04-10 09:55:00-04:00,BCLI,positive
147847.0,BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn™ in ALS,2015-02-03 07:23:00-05:00,BCLI,positive
147848.0,BrainStorm Announces Positive Results from Preclinical Studies of NurOwn in Mouse Autism Model,2015-01-26 09:07:00-05:00,BCLI,positive
147849.0,BiotechBreakthroughs @BioBreakthrough Tweet $BCLI shares of this recent biotech runner have bottomed. Long $3.8s.,2015-01-16 10:48:00-05:00,BCLI,positive
147850.0,What Investors Are Looking At In The Stem Cell Sector,2015-01-13 11:48:00-05:00,BCLI,neutral
147851.0,Brainstorm Cell Therapuetics Holders Have Agreed to Exercise Their Warrants at  Exercise Price of $5.22/Share,2015-01-08 09:52:00-05:00,BCLI,positive
147852.0,BrainStorm Announces Receipt Of ~$3.1M From Warrant Exercises,2015-01-07 08:24:00-05:00,BCLI,neutral
147853.0,Morning Market Losers,2015-01-05 09:57:00-05:00,BCLI,negative
147854.0,"Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm Cell Therapeutics And More",2015-01-05 09:31:00-05:00,BCLI,neutral
147855.0,UPDATE: Brainstorm Cell Therapeutics President Says has Not Sold Any Shares,2015-01-05 09:21:00-05:00,BCLI,negative
147856.0,UPDATE: Brainstorm Cell Therapeutcs Says Study Achieved Primary Endpoint,2015-01-05 08:21:00-05:00,BCLI,neutral
147857.0,BrainStorm Announces Positive Final Analysis Of Phase 2a ALS Study,2015-01-05 08:21:00-05:00,BCLI,positive
147858.0,"BrainStorm Cell Therapeutics Says Final Results from Clinical Trial of Adult Stem Cell Treatment in ALS were Positive, Most Patients Showing Slowing in Disease's Progression",2015-01-05 08:17:00-05:00,BCLI,positive
147859.0,Stocks Hitting 52-Week Highs,2015-01-02 10:18:00-05:00,BCLI,neutral
147860.0,Morning Market Movers,2015-01-02 09:39:00-05:00,BCLI,neutral
147861.0,"UPDATE: Brainstorm Cell Therapeutics Shares Spike Higher at Open, Now Up 75%",2015-01-02 09:33:00-05:00,BCLI,positive
147862.0,Brainstorm Cell Therapeutics Soars 45%,2015-01-02 08:57:00-05:00,BCLI,neutral
147863.0,Benzinga's Top #PreMarket Gainers,2015-01-02 08:38:00-05:00,BCLI,positive
147864.0,UPDATE: BrainStorm Cell Therapeutics Shares Rise 44% Premarket Ahead of January 5 ALS Data,2015-01-02 08:13:00-05:00,BCLI,positive
147865.0,BrainStorm Cell Therapeutics Shares Rise 14% Premarket Ahead of January 5 Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn in ALS,2015-01-02 07:24:00-05:00,BCLI,positive
147866.0,What Investors Are Looking For In Brainstorm Cell Therapeutics' Upcoming Clinical Results,2014-12-31 16:02:00-05:00,BCLI,neutral
147867.0,BrainStorm Cell Therapeutics Shares Rise 10% Ahead of January 5 Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn in ALS,2014-12-31 09:49:00-05:00,BCLI,positive
147868.0,Brainstorm Cell Therapeutics Shares Rise in Premarket on Positive Adam F/Street.com Article ,2014-10-16 08:52:00-04:00,BCLI,positive
147869.0,Brainstorm Cell Therapeutics Reports FDA Fast Track Designation for NurOwn for Treatment of ALS,2014-10-07 07:08:00-04:00,BCLI,neutral
147870.0,FDA Approves Commencement of BrainStorm's Phase II ALS Clinical Trial,2014-04-28 06:45:00-04:00,BCLI,positive
147871.0,"BrainStorm, Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial ",2014-03-25 06:00:00-04:00,BCLI,positive
147872.0,BrainStorm Enters Into Agreement with Pharmanet for ALS Trial Development,2011-07-22 08:36:00-04:00,BCLI,positive
147873.0,  BrainStorm Initiates Clinical Trials and Holds Successful Shareholders Meeting,2011-06-13 10:05:00-04:00,BCLI,positive
147874.0,BrainStorm Announces Resignation of CEO ,2010-12-13 10:54:00-05:00,BCLI,negative
